Australia markets closed

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
7.650+0.250 (+3.38%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 5.25B
Enterprise value 5.40B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.95
Price/book (mrq)3.61
Enterprise value/revenue 7.01
Enterprise value/EBITDA -32.96

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-64.76%
S&P500 52-week change 323.20%
52-week high 321.500
52-week low 35.740
50-day moving average 38.542
200-day moving average 310.273

Share statistics

Avg vol (3-month) 3132.74k
Avg vol (10-day) 3125.35k
Shares outstanding 5109.63M
Implied shares outstanding 6399.4M
Float 843.02M
% held by insiders 138.76%
% held by institutions 118.37%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -53.42%
Operating margin (ttm)-34.67%

Management effectiveness

Return on assets (ttm)-6.94%
Return on equity (ttm)-39.45%

Income statement

Revenue (ttm)716.91M
Revenue per share (ttm)1.80
Quarterly revenue growth (yoy)28.00%
Gross profit (ttm)N/A
EBITDA -151.63M
Net income avi to common (ttm)-382.95M
Diluted EPS (ttm)-1.030
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)434.04M
Total cash per share (mrq)1.09
Total debt (mrq)544.11M
Total debt/equity (mrq)68.84%
Current ratio (mrq)1.25
Book value per share (mrq)1.97

Cash flow statement

Operating cash flow (ttm)-76.65M
Levered free cash flow (ttm)-231.5M